US5286497A
(en)
*
|
1991-05-20 |
1994-02-15 |
Carderm Capital L.P. |
Diltiazem formulation
|
US5914132A
(en)
*
|
1993-02-26 |
1999-06-22 |
The Procter & Gamble Company |
Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
|
WO1995003052A1
(en)
*
|
1993-07-22 |
1995-02-02 |
Warner-Lambert Company |
Controlled release tacrine drug delivery systems and methods for preparing same
|
US5395626A
(en)
*
|
1994-03-23 |
1995-03-07 |
Ortho Pharmaceutical Corporation |
Multilayered controlled release pharmaceutical dosage form
|
AT403988B
(de)
*
|
1994-05-18 |
1998-07-27 |
Lannacher Heilmittel |
Festes orales retardpräparat
|
US5645858A
(en)
*
|
1994-10-06 |
1997-07-08 |
Ortho Pharmaceutical Corporation |
Multilayered controlled release pharmaceutical dosage form
|
US5834024A
(en)
*
|
1995-01-05 |
1998-11-10 |
Fh Faulding & Co. Limited |
Controlled absorption diltiazem pharmaceutical formulation
|
US5567441A
(en)
*
|
1995-03-24 |
1996-10-22 |
Andrx Pharmaceuticals Inc. |
Diltiazem controlled release formulation
|
US5686106A
(en)
*
|
1995-05-17 |
1997-11-11 |
The Procter & Gamble Company |
Pharmaceutical dosage form for colonic delivery
|
FR2742660B1
(fr)
|
1995-12-22 |
1998-04-03 |
Ethypharm Lab Prod Ethiques |
Nouvelles formes de microgranules a liberation prolongee contenant du diltiazem comme principe actif
|
US20030215507A1
(en)
*
|
1996-03-25 |
2003-11-20 |
Wyeth |
Extended release formulation
|
US20060068000A1
(en)
*
|
1996-03-25 |
2006-03-30 |
Wyeth |
Extended release formulation
|
US8071128B2
(en)
|
1996-06-14 |
2011-12-06 |
Kyowa Hakko Kirin Co., Ltd. |
Intrabuccally rapidly disintegrating tablet and a production method of the tablets
|
US5830503A
(en)
*
|
1996-06-21 |
1998-11-03 |
Andrx Pharmaceuticals, Inc. |
Enteric coated diltiazem once-a-day formulation
|
KR100522248B1
(ko)
*
|
1997-05-29 |
2006-02-01 |
동아제약주식회사 |
이중제어방출막구조의경구서방성제제및그제조방법
|
US6524620B2
(en)
*
|
1998-07-20 |
2003-02-25 |
Andrx Pharmaceuticals, Inc. |
Diltiazem controlled release formulation and method of manufacture
|
US6270805B1
(en)
*
|
1998-11-06 |
2001-08-07 |
Andrx Pharmaceuticals, Inc. |
Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
|
PL349501A1
(en)
*
|
1998-12-24 |
2002-07-29 |
Janssen Pharmaceutica Nv |
Controlled release galantamine composition
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6245913B1
(en)
|
1999-06-30 |
2001-06-12 |
Wockhardt Europe Limited |
Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
|
US7108866B1
(en)
*
|
1999-12-10 |
2006-09-19 |
Biovall Laboratories International Srl |
Chronotherapeutic diltiazem formulations and the administration thereof
|
US20060153914A1
(en)
*
|
1999-12-10 |
2006-07-13 |
Biovail Laboratories International S.R.L. |
Chronotherapeutic diltiazem formulations and the administration thereof
|
US6627223B2
(en)
*
|
2000-02-11 |
2003-09-30 |
Eurand Pharmaceuticals Ltd. |
Timed pulsatile drug delivery systems
|
US6635277B2
(en)
|
2000-04-12 |
2003-10-21 |
Wockhardt Limited |
Composition for pulsatile delivery of diltiazem and process of manufacture
|
US6984402B2
(en)
|
2000-10-03 |
2006-01-10 |
Elite Laboratories, Inc. |
Chrono delivery formulations and method of treating atrial fibrillation
|
US6620439B1
(en)
*
|
2000-10-03 |
2003-09-16 |
Atul M. Mehta |
Chrono delivery formulations and method of use thereof
|
US6287599B1
(en)
*
|
2000-12-20 |
2001-09-11 |
Shire Laboratories, Inc. |
Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
|
JP4848101B2
(ja)
*
|
2001-08-17 |
2011-12-28 |
株式会社フジモト・コーポレーション |
徐放性マイクロペレット
|
US9358214B2
(en)
|
2001-10-04 |
2016-06-07 |
Adare Pharmaceuticals, Inc. |
Timed, sustained release systems for propranolol
|
US6500454B1
(en)
*
|
2001-10-04 |
2002-12-31 |
Eurand Pharmaceuticals Ltd. |
Timed, sustained release systems for propranolol
|
US6663888B2
(en)
|
2001-12-14 |
2003-12-16 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
US20050025824A1
(en)
*
|
2001-12-14 |
2005-02-03 |
Eurand Pharmaceuticals Ltd. |
Pulsatile release histamine H2 antagonist dosage form
|
WO2003096874A2
(en)
*
|
2002-05-15 |
2003-11-27 |
Sun Pharmaceutical Industries Limited |
Coated sustained release tablets of a hygroscopic compound for once-a-day therapy
|
WO2004022038A1
(en)
*
|
2002-09-09 |
2004-03-18 |
Biovail Laboratorties Inc. |
Chronotherapeutic diltiazem formulations and the administration thereof
|
MY148805A
(en)
*
|
2002-10-16 |
2013-05-31 |
Takeda Pharmaceutical |
Controlled release preparation
|
US9107804B2
(en)
*
|
2002-12-10 |
2015-08-18 |
Nortec Development Associates, Inc. |
Method of preparing biologically active formulations
|
US8367111B2
(en)
|
2002-12-31 |
2013-02-05 |
Aptalis Pharmatech, Inc. |
Extended release dosage forms of propranolol hydrochloride
|
US20050025825A1
(en)
*
|
2003-07-31 |
2005-02-03 |
Xanodyne Pharmacal, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
US20090214644A1
(en)
*
|
2003-07-31 |
2009-08-27 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations with reduced adverse effects
|
WO2005019163A2
(en)
*
|
2003-08-20 |
2005-03-03 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
|
EP2354120A1
(de)
|
2003-08-20 |
2011-08-10 |
XenoPort, Inc. |
Synthese von Acyloxyalkylcarbamat-Prodrugs und Zwischenprodukten davon
|
US20050244495A1
(en)
*
|
2004-03-04 |
2005-11-03 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations
|
US7947739B2
(en)
|
2004-03-04 |
2011-05-24 |
Ferring B.V. |
Tranexamic acid formulations
|
US20050245614A1
(en)
*
|
2004-03-04 |
2005-11-03 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations
|
US8022106B2
(en)
*
|
2004-03-04 |
2011-09-20 |
Ferring B.V. |
Tranexamic acid formulations
|
US20090215898A1
(en)
*
|
2004-03-04 |
2009-08-27 |
Xanodyne Pharmaceuticals, Inc. |
Tranexamic acid formulations
|
JP2007532623A
(ja)
*
|
2004-04-12 |
2007-11-15 |
ファイザー・プロダクツ・インク |
破裂型多重粒子中の味マスキング薬物
|
US8747895B2
(en)
|
2004-09-13 |
2014-06-10 |
Aptalis Pharmatech, Inc. |
Orally disintegrating tablets of atomoxetine
|
US9884014B2
(en)
|
2004-10-12 |
2018-02-06 |
Adare Pharmaceuticals, Inc. |
Taste-masked pharmaceutical compositions
|
EP1802285B1
(de)
|
2004-10-21 |
2013-02-27 |
Aptalis Pharmatech, Inc. |
Geschmacksverdeckende pharmazeutische zusammensetzungen mit magenlöslichen porenbildnern
|
US7566738B2
(en)
*
|
2004-11-03 |
2009-07-28 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
|
US7494985B2
(en)
*
|
2004-11-03 |
2009-02-24 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
|
US9161918B2
(en)
*
|
2005-05-02 |
2015-10-20 |
Adare Pharmaceuticals, Inc. |
Timed, pulsatile release systems
|
AU2006262386B2
(en)
*
|
2005-06-20 |
2012-02-02 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
|
CN101316602B
(zh)
|
2005-09-27 |
2015-06-03 |
组织技术公司 |
羊膜制品和纯化的组合物及其使用方法
|
US8187639B2
(en)
|
2005-09-27 |
2012-05-29 |
Tissue Tech, Inc. |
Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
|
ES2812250T3
(es)
|
2005-11-28 |
2021-03-16 |
Marinus Pharmaceuticals Inc |
Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
|
US20080090897A1
(en)
|
2006-08-11 |
2008-04-17 |
The Johns Hopkins University |
Compositions and methods for neuroprotectin
|
US7585996B2
(en)
*
|
2006-09-15 |
2009-09-08 |
Xenoport, Inc. |
Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
|
SI2526934T1
(sl)
|
2006-09-22 |
2016-04-29 |
Pharmacyclics Llc |
Inhibitorji Bruton tirozin kinaze
|
US11116728B2
(en)
|
2006-11-30 |
2021-09-14 |
Bend Research, Inc. |
Multiparticulates of spray-coated drug and polymer on a meltable core
|
US10357462B2
(en)
*
|
2006-11-30 |
2019-07-23 |
Ben Research, Inc. |
Multiparticulates of spray-coated drug and polymer on a meltable core
|
EP2101752A1
(de)
*
|
2006-12-08 |
2009-09-23 |
Xenoport, Inc. |
Verwendung prodrugs von gaba-analoga zur behandlung von erkrankungen
|
PL2099442T3
(pl)
|
2006-12-26 |
2015-04-30 |
Pharmacyclics Inc |
Sposób stosowania inhibitorów deacetylazy histonów i monitoringu biomarkerów w terapii skojarzonej
|
AU2008299220B2
(en)
|
2007-09-10 |
2011-07-21 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US20100034968A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Vector Corporation |
Polymer coating process using dry glidant in a rotor processor
|
US8807070B2
(en)
*
|
2008-08-07 |
2014-08-19 |
Vector Corporation |
Rotor processor for dry powders
|
US20100034967A1
(en)
*
|
2008-08-07 |
2010-02-11 |
Vector Corporation |
Dry polymer layering using a rotor processor
|
MX2011002149A
(es)
|
2008-08-27 |
2011-04-05 |
Calcimedica Inc |
Compuestos que modulan el calcio intracelular.
|
WO2010071866A2
(en)
|
2008-12-19 |
2010-06-24 |
Nuon Therapeutics, Inc. |
Combination therapy for arthritis with tranilast
|
EP3045043B1
(de)
|
2009-02-26 |
2020-04-29 |
Relmada Therapeutics, Inc. |
Oral einnehmbare pharmazeutische zusammensetzungen aus 3-hydroxy-n-methylmorphinan mit verzögerter freisetzung und verwendungsverfahren dafür
|
US8603521B2
(en)
|
2009-04-17 |
2013-12-10 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor and uses thereof
|
EP2421901B1
(de)
|
2009-04-24 |
2015-10-28 |
Tissue Tech, Inc. |
Zusammensetzungen mit hc-ha-komplex und verfahren zu ihrer verwendung
|
US20100280117A1
(en)
*
|
2009-04-30 |
2010-11-04 |
Xanodyne Pharmaceuticals, Inc. |
Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
|
US9078830B2
(en)
|
2009-07-31 |
2015-07-14 |
Ranbaxy Laboratories Limited |
Multi-layered, multiple unit pharmaceutical compositions
|
IN2012DN00754A
(de)
|
2009-08-04 |
2015-06-19 |
Amira Pharmaceuticals Inc |
|
WO2011028234A1
(en)
*
|
2009-09-04 |
2011-03-10 |
Xenoport, Inc. |
Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
|
GB2474120B
(en)
|
2009-10-01 |
2011-12-21 |
Amira Pharmaceuticals Inc |
Compounds as Lysophosphatidic acid receptor antagonists
|
US7718662B1
(en)
|
2009-10-12 |
2010-05-18 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
|
AU2010325746B2
(en)
|
2009-12-02 |
2016-02-25 |
Adare Pharmaceuticals S.R.L. |
Fexofenadine microcapsules and compositions containing them
|
EP2536708A4
(de)
|
2010-02-16 |
2013-05-29 |
Aragon Pharmaceuticals Inc |
Androgenrezeptormodulatoren und ihre verwendung
|
ES2602475T3
(es)
|
2010-04-15 |
2017-02-21 |
Tracon Pharmaceuticals, Inc. |
Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
|
CA2797663C
(en)
|
2010-04-27 |
2018-10-09 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
AU2011248579A1
(en)
|
2010-04-27 |
2012-11-29 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
ES2688072T3
(es)
|
2010-05-11 |
2018-10-30 |
Mallinckrodt Ard Ip Limited |
ACTH para el tratamiento de la esclerosis lateral amiotrófica
|
EP3205648A1
(de)
|
2010-06-10 |
2017-08-16 |
Seragon Pharmaceuticals, Inc. |
Östrogenrezeptormodulatoren und verwendungen davon
|
CN114591311A
(zh)
|
2010-08-27 |
2022-06-07 |
钙医学公司 |
调节细胞内钙的化合物
|
US8796416B1
(en)
|
2010-10-25 |
2014-08-05 |
Questcor Pharmaceuticals, Inc |
ACTH prophylactic treatment of renal disorders
|
PE20140879A1
(es)
|
2010-12-07 |
2014-08-06 |
Amira Pharmaceuticals Inc |
Antagonistas del receptor de acido lisofosfatidico para el tratamiento de fibrosis
|
US9526770B2
(en)
|
2011-04-28 |
2016-12-27 |
Tissuetech, Inc. |
Methods of modulating bone remodeling
|
WO2012166415A1
(en)
|
2011-05-27 |
2012-12-06 |
Amira Pharmaceuticals, Inc. |
Heterocyclic autotaxin inhibitors and uses thereof
|
WO2012170905A1
(en)
|
2011-06-10 |
2012-12-13 |
Tissuetech, Inc. |
Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
|
CA2845806C
(en)
|
2011-09-13 |
2019-06-11 |
Pharmacyclics, Inc. |
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
JP6154887B2
(ja)
|
2012-03-20 |
2017-06-28 |
セラゴン ファーマシューティカルズ,インク. |
エストロゲン受容体モジュレーターおよびその使用
|
EP2872181B1
(de)
|
2012-07-11 |
2020-11-18 |
Tissuetech, Inc. |
Zusammensetzungen mit hc-ha/ptx3-komplexen und verfahren zur verwendung davon
|
AR091858A1
(es)
|
2012-07-25 |
2015-03-04 |
Sova Pharmaceuticals Inc |
INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
|
AR091857A1
(es)
|
2012-07-25 |
2015-03-04 |
Sova Pharmaceuticals Inc |
INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
|
CN104661658A
(zh)
|
2012-09-26 |
2015-05-27 |
阿拉贡药品公司 |
用于治疗非转移性去势抵抗性前列腺癌的抗雄激素
|
EP2900674B1
(de)
|
2012-09-28 |
2017-05-31 |
University of Washington through its Center for Commercialization |
Verbindungen und verfahren zur vorbeugung, behandlung und/oder schutz vor haarzelltod
|
US9512116B2
(en)
|
2012-10-12 |
2016-12-06 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
KR101340733B1
(ko)
*
|
2012-12-31 |
2013-12-12 |
(주) 에프엔지리서치 |
신규한 마이크로그래뉼 제형
|
JOP20200097A1
(ar)
|
2013-01-15 |
2017-06-16 |
Aragon Pharmaceuticals Inc |
معدل مستقبل أندروجين واستخداماته
|
WO2014153221A2
(en)
|
2013-03-14 |
2014-09-25 |
Questcor Pharmaceuticals, Inc. |
Acth for treatment of acute respiratory distress syndrome
|
BR112015031903A8
(pt)
|
2013-06-19 |
2019-12-31 |
Seragon Pharmaceuticals Inc |
composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
|
KR20160021281A
(ko)
|
2013-06-19 |
2016-02-24 |
세라곤 파마슈티컬스, 인크. |
아제티딘 에스트로겐 수용체 조절제 및 이의 용도
|
WO2015054283A1
(en)
|
2013-10-08 |
2015-04-16 |
Calcimedica, Inc. |
Compounds that modulate intracellular calcium
|
US9382246B2
(en)
|
2013-12-05 |
2016-07-05 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
AU2014246617A1
(en)
|
2013-12-23 |
2015-07-09 |
Sun Pharmaceutical Industries Limited |
Multi-layered, multiple unit pharmaceutical compositions
|
TW201603818A
(zh)
|
2014-06-03 |
2016-02-01 |
組織科技股份有限公司 |
組成物及方法
|
US9839644B2
(en)
|
2014-09-09 |
2017-12-12 |
ARKAY Therapeutics, LLC |
Formulations and methods for treatment of metabolic syndrome
|
US9359316B1
(en)
|
2014-11-25 |
2016-06-07 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists
|
EP3253766B1
(de)
|
2015-02-06 |
2019-09-04 |
University of Washington |
Verbindungen und verfahren zur vorbeugung oder behandlung von sensorischem haarzelltod
|
US10227333B2
(en)
|
2015-02-11 |
2019-03-12 |
Curtana Pharmaceuticals, Inc. |
Inhibition of OLIG2 activity
|
WO2016138025A2
(en)
|
2015-02-23 |
2016-09-01 |
Tissuetech, Inc. |
Apparatuses and methods for treating ophthalmic diseases and disorders
|
AU2016225000B2
(en)
|
2015-02-27 |
2021-04-01 |
Curtana Pharmaceuticals, Inc. |
Inhibition of Olig2 activity
|
JP2018516869A
(ja)
|
2015-05-20 |
2018-06-28 |
ティッシュテック,インク. |
上皮細胞の増殖および上皮間葉転換を防ぐための組成物および方法
|
US9637514B1
(en)
|
2015-10-26 |
2017-05-02 |
MAX BioPharma, Inc. |
Oxysterols and hedgehog signaling
|
EP3368543B1
(de)
|
2015-10-26 |
2020-09-23 |
MAX Biopharma, Inc. |
Oxysterole und hedgehog-signalisierung
|
EP4253412A3
(de)
|
2015-12-16 |
2023-11-22 |
The Walter and Eliza Hall Institute of Medical Research |
Hemmung von cytokininduziertem sh2-protein in nk-zellen
|
TWI726969B
(zh)
|
2016-01-11 |
2021-05-11 |
比利時商健生藥品公司 |
用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
|
TW201733600A
(zh)
|
2016-01-29 |
2017-10-01 |
帝聖工業公司 |
胎兒扶持組織物及使用方法
|
WO2017147146A1
(en)
|
2016-02-23 |
2017-08-31 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic trpv1 agonists
|
US10821105B2
(en)
|
2016-05-25 |
2020-11-03 |
Concentric Analgesics, Inc. |
Prodrugs of phenolic TRPV1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
|
WO2017205766A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205769A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2017205762A1
(en)
|
2016-05-27 |
2017-11-30 |
Pharmacyclics Llc |
Inhibitors of interleukin-1 receptor-associated kinase
|
WO2018039621A1
(en)
|
2016-08-26 |
2018-03-01 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
CN111479560A
(zh)
|
2017-10-16 |
2020-07-31 |
阿拉贡药品公司 |
用于治疗非转移性去势难治性前列腺癌的抗雄激素
|
WO2019090205A1
(en)
|
2017-11-06 |
2019-05-09 |
Snap Bio, Inc. |
Pim kinase inhibitor compositions, methods, and uses thereof
|
WO2019169112A1
(en)
|
2018-02-28 |
2019-09-06 |
Curtana Pharmaceuticals, Inc. |
Inhibition of olig2 activity
|
CA3098720A1
(en)
|
2018-04-30 |
2019-11-07 |
Cedars-Sinai Medical Center |
Methods and systems for selection and treatment of patients with inflammatory diseases
|
AU2019310118A1
(en)
|
2018-07-27 |
2021-03-11 |
Concentric Analgesics, Inc. |
Pegylated prodrugs of phenolic TRPV1 agonists
|
CA3125350A1
(en)
|
2018-12-31 |
2020-07-09 |
Biomea Fusion, Llc |
Irreversible inhibitors of menin-mll interaction
|
KR20220009373A
(ko)
|
2019-03-15 |
2022-01-24 |
유니사이시브 테라퓨틱스 인코포레이티드 |
니코란딜 유도체
|
EP3946547A4
(de)
|
2019-03-26 |
2023-01-18 |
Pocket Naloxone Corp. |
Vorrichtungen und verfahren zur abgabe von pharmazeutischen zusammensetzungen
|
BR112021022789A2
(pt)
|
2019-05-14 |
2022-04-19 |
Cedars Sinai Medical Center |
Métodos, sistemas e dispositivos para a seleção de pacientes para tl1a
|
MA56541A
(fr)
|
2019-06-21 |
2022-04-27 |
Entelexo Biotherapeutics Inc |
Plateformes, compositions et méthodes d'administration de composés thérapeutiques
|
EP4263542A1
(de)
|
2020-12-16 |
2023-10-25 |
Biomea Fusion, Inc. |
Kondensierte pyrimidinverbindungen als inhibitoren der menin-mll-interaktion
|
WO2022150525A1
(en)
|
2021-01-06 |
2022-07-14 |
Awakn Life Sciences |
Mdma in the treatment of alcohol use disorder
|
US11278709B1
(en)
|
2021-03-12 |
2022-03-22 |
Pocket Naloxone Corp. |
Drug delivery device and methods for using same
|
EP4337316A1
(de)
|
2021-05-11 |
2024-03-20 |
Awakn Ls Europe Holdings Limited |
Therapeutische aminoindanverbindungen und zusammensetzungen
|
WO2022256720A2
(en)
|
2021-06-03 |
2022-12-08 |
Arcadia Medicine, Inc. |
Enantiomeric entactogen compositions and methods of their use
|
WO2023018825A1
(en)
|
2021-08-11 |
2023-02-16 |
Biomea Fusion, Inc. |
Covalent inhibitors of menin-mll interaction for diabetes mellitus
|
WO2023027966A1
(en)
|
2021-08-24 |
2023-03-02 |
Biomea Fusion, Inc. |
Pyrazine compounds as irreversible inhibitors of flt3
|
WO2023039240A1
(en)
|
2021-09-13 |
2023-03-16 |
Biomea Fusion, Inc. |
IRREVERSIBLE INHIBITORS OF KRas
|
WO2023086341A1
(en)
|
2021-11-09 |
2023-05-19 |
Biomea Fusion, Inc. |
Inhibitors of kras
|
WO2023129667A1
(en)
|
2021-12-30 |
2023-07-06 |
Biomea Fusion, Inc. |
Pyrazine compounds as inhibitors of flt3
|
WO2023139163A1
(en)
|
2022-01-19 |
2023-07-27 |
Awakn Ls Europe Holdings Limited |
1,3-benzodioxole esters and their therapeutic use
|
WO2023156565A1
(en)
|
2022-02-16 |
2023-08-24 |
Awakn Ls Europe Holdings Limited |
Bridged ring compounds and their therapeutic use as cns agents
|
WO2023235618A1
(en)
|
2022-06-03 |
2023-12-07 |
Biomea Fusion, Inc. |
Fused pyrimidine compounds as inhibitors of menin
|